Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP3A51/3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole.

Pharmacogenetics and genomics - 1 Jun 2009

Chandel Nirupama, Aggarwal Pardeep K, Minz Mukut, Sakhuja Vinay, Kohli Krishan K, Jha Vivekanand

Abstract excerpt

OBJECTIVES: Ketoconazole retards metabolic degradation of tacrolimus through its effect on the cytochrome P-450 enzyme system and allows reduction in treatment costs. Enzyme activity is determined by a single nucleotide polymorphism (*1/*3) in the CYP3A5 gene. METHODS: We prospectively investigat...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antifungal Agents
Share to Cytochrome P-450 CYP3A
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to Metabolic Clearance Rate

Share to Polymorphism, Single Nucleotide

Share to Renal Transplantation Outcomes and Treatments

Share to Tacrolimus

Source

Identifiers

PMID: 19384264
DOI: 10.1097/FPC.0b013e32832bd085

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19384264-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole.PMID 19384264Read ↗

Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.Semantic proximity Read ↗

CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients.Semantic proximity Read ↗

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.Semantic proximity Read ↗

The pharmacogenetics of Tacrolimus in Algerian kidney recipients' patients.Semantic proximity Read ↗

Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients.Semantic proximity Read ↗

Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.Semantic proximity Read ↗

Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients.Semantic proximity Read ↗

Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.Semantic proximity Read ↗

Genetic polymorphisms and individualized tacrolimus dosing.Semantic proximity Read ↗

A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.Semantic proximity Read ↗

Genotype-guided tacrolimus dosing: The role of CYP3A5 polymorphisms in optimising kidney transplant immunosuppression in BhutanSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.